Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2021-12-28 Governance Information
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
网络投票实施细则
Governance Information Classification · 95% confidence The document is titled as an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the implementation rules for online voting at the shareholders' meeting. It details the procedures, rules, and regulations for conducting network voting for the shareholders' meeting, including voting rights, preparation, and vote counting. There is no financial data, no report of financial results, no audit information, no management discussion, or any other financial or regulatory filing content. The document is a governance-related announcement about shareholder meeting voting procedures, which fits best under Governance Information (CGR). The document length is 2552 characters, which is relatively short but contains substantive governance content rather than a mere announcement of a report publication or a regulatory filing. Therefore, the classification is Governance Information (CGR) with high confidence.
2021-12-28 Chinese
内部审计管理制度
Audit Report / Information Classification · 95% confidence The document is titled as an internal audit management system of Jiangsu Deyuan Pharmaceutical Co., Ltd., approved by the board of directors. It details the internal audit policies, procedures, responsibilities, and control mechanisms within the company. It is a comprehensive internal control and audit management document, not a financial report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a brief announcement or a certification. It is a detailed internal audit policy document, which fits the category of Audit Report / Information (AR), as it relates to internal audit management and control systems rather than a full annual report or other categories. FY 2021
2021-12-28 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for related party transactions (关联交易管理制度) issued by Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the company's internal rules and procedures regarding related party transactions, including definitions, decision-making processes, disclosure requirements, and compliance with laws and regulations. The document is a formal policy or governance document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it an announcement of a report publication. It is clearly a governance-related document outlining internal control and compliance procedures for related party transactions. Therefore, the most appropriate classification is Governance Information (CGR). The document length (5434 characters) supports it being a substantive policy document rather than a brief announcement.
2021-12-28 Chinese
独立董事关于第三届董事会第八次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the independent directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding their independent opinions on matters discussed at the company's third board of directors' eighth meeting. It includes opinions on proposals related to amendments to the profit distribution management system and anticipated related party transactions for 2022. The document is a regulatory announcement about board meeting opinions and does not contain financial statements or detailed financial data. It is not a full annual or interim report, nor is it a call transcript or earnings release. It fits best under Regulatory Filings (RNS) as it is a compliance-related announcement about board meeting matters and independent director opinions.
2021-12-28 Chinese
年报信息披露重大差错责任追究制度
Governance Information Classification · 95% confidence The document is titled as a system for accountability regarding major errors in annual report information disclosure. It discusses the responsibilities, standards for identifying major errors in annual reports, procedures for accountability, and related governance measures. The content is focused on internal control, error correction, and responsibility related to annual report disclosures, rather than the annual report itself or an announcement of a report. It is a governance-related document detailing internal rules and procedures for handling annual report errors. The document length is under 5,000 characters, but it is not a brief announcement or a report publication notice; it is a detailed policy document. Therefore, it fits best under Governance Information (CGR).
2021-12-28 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" issued by the company's board. It details the company's policies, principles, organizational structure, and procedures for managing investor relations, including communication, disclosure, and handling of investor-related events. There are no financial statements, earnings data, or audit information present. The document is a governance-related policy document rather than a financial report or announcement. It is not a report publication announcement or a brief notice but a substantive governance document. Therefore, the most appropriate classification is Governance Information (CGR).
2021-12-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.